Factors associated with high cardiovascular risk in psoriatic arthritis and non-psoriatic spondyloarthritis

Patients on peritoneal dialysis (PD) are at high cardiovascular risk. Although some risk factors are unmodifiable (for example, age, sex, genetics), others are exacerbated in the unfriendly uremic milieu (inflammation, oxidative stress, mineral disturbances) or contribute per se to kidney disease and cardiovascular progression (diabetes mellitus, hypertension). Moreover, several factors associated with PD therapy may both increase (by altered lipid profile, hyperinsulinemia, and formation of advanced glycation end-products) and decrease (by better blood pressure control and anemia management) cardiovascular risk. The present review discusses recent findings and therapy trends in cardiovascular research on the PD population, with emphasis on the roles of inflammation, insulin resistance, homocysteinemia, dyslipidemia, vascular calcification, and genetics/epigenetics.

Download Full-text

Large auto-hemoinfusion versus rectal insufflation in patients with metabolic syndrome

Ozone Therapy ◽

10.4081/ozone.2016.5841 ◽

2016 ◽

Vol 1 (1) ◽

pp. 13

Author(s):

Francesco Vaiano ◽

Fortunato Loprete

Keyword(s):

Metabolic Syndrome ◽

Cardiovascular Risk ◽

Clinical Situation ◽

Gas Mixture ◽

High Cardiovascular Risk ◽

Factors Associated ◽

The Metabolic Syndrome ◽

Alternative Method

The metabolic syndrome is a clinical situation including a series of factors at high cardiovascular risk; the treatment with an oxygenozone gas mixture can influence all factors associated with this syndrome. The objective of the study has been to verify if the rectal insufflation could replace the large auto-hemoinfusion when treating the metabolic syndrome in those patients who, for various reasons cannot use the auto-hemoinfusion. Twenty-four individuals aged between 34 and 68 were recruited and included in the group treated with ozonated auto-hemoinfusion and other 24 individuals aged between 35 and 67 were recruited and included in the group treated with rectal insufflation of the oxygen-ozone gas mixture. According to the results obtained by means of oxygen-ozone mixture rectal insufflation, which are almost equivalent to the results obtained with the large ozonated auto-hemoinfusion, authors could conclude that the ozonated rectal insufflation can be taken into consideration as alternative method to the large auto-hemoinfusion, while treating the metabolic syndrome, in those patients difficult to manage due to the previously described reasons.

Download Full-text

Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: An analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry

Atherosclerosis ◽

10.1016/j.atherosclerosis.2021.08.024 ◽

2021 ◽

Author(s):

Krzysztof Dyrbuś ◽

Mariusz Gąsior ◽

Piotr Desperak ◽

Przemysław Trzeciak ◽

Jolanta Nowak ◽

...

Keyword(s):

Risk Factors ◽

Myocardial Infarction ◽

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Factors Associated ◽

Long Term Mortality

Download Full-text

Factors associated with levels of interleukins -18, -8, and -6 in hypertensive patients at high and very high cardiovascular risk

Kardiologiia ◽

10.18087/cardio.2410 ◽

2017 ◽

Vol 17 (S3) ◽

pp. 69-75 ◽

Cited By ~ 1

Author(s):

G. P. Arutyunov ◽

◽

D. O. Dragunov ◽

A. V. Sokolova ◽

V. M. Mitrokhin ◽

...

Keyword(s):

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Hypertensive Patients ◽

Factors Associated ◽

Very High

Download Full-text

Factors associated with high cardiovascular risk in a primarily African American, urban HIV-infected population

SAGE Open Medicine ◽

10.1177/2050312117725644 ◽

2017 ◽

Vol 5 ◽

pp. 205031211772564 ◽

Cited By ~ 1

Author(s):

Shashwatee Bagchi ◽

Shana AB Burrowes ◽

Lori E Fantry ◽

Mian B Hossain ◽

Gemechis H Tollera ◽

...

Keyword(s):

African American ◽

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Factors Associated ◽

Infected Population

Download Full-text

Hyperuricemia as risk factor for cardiovascular disease – what’s new?

Medical alphabet ◽

10.33667/2078-5631-2020-13-5-11 ◽

2020 ◽

pp. 5-11

Author(s):

Yu. V. Zhernakova

Keyword(s):

Cardiovascular Disease ◽

Chronic Kidney Disease ◽

Uric Acid ◽

Cardiovascular Risk ◽

Epidemiological Studies ◽

Point Of View ◽

Medical Society ◽

High Cardiovascular Risk ◽

Management Algorithm ◽

Russian Medical

A significant number of epidemiological studies have shown that hyperuricemia is highly associated with the risk of developing cardiovascular disease, chronic kidney disease, and diabetes. In this connection, increased attention is required to monitor serum uric acid levels in patients, not only from a rheumatological point of view, but also with regard to reducing cardiovascular and renal risks. This article is a review of studies on the association of hyperuricemia with cardiovascular risk and a new consensus for the management of patients with hyperuricemia and high cardiovascular risk, published in december 2019 by a group of experts of the Russian Medical Society for Arterial Hypertension, which, among other things, includes a management algorithm of this category of patients.

Download Full-text

The effect of PCSK9 Inhibitor EVOLOCUMAB on aldosterone among high cardiovascular risk patients

Endocrine Abstracts ◽

10.1530/endoabs.70.ep124 ◽

2020 ◽

Author(s):

Elena Lzkhakov ◽

Yakov Shacham ◽

Mariana Yaron ◽

Merav Serebro ◽

Karen Tordjman ◽

...

Keyword(s):

Cardiovascular Risk ◽

High Cardiovascular Risk ◽

Pcsk9 Inhibitor ◽

Risk Patients

Download Full-text

Telmisartan in High Cardiovascular Risk Patients

European Cardiology Review ◽

10.15420/ecr.2012.8.1.10 ◽

2012 ◽

Vol 8 (1) ◽

pp. 10 ◽

Cited By ~ 1

Author(s):

Roland Asmar ◽

Keyword(s):

Cardiovascular Disease ◽

Cardiovascular Risk ◽

Ace Inhibitors ◽

Angiotensin Receptor Blockers ◽

High Cardiovascular Risk ◽

Raas Blockade ◽

Risk Patients ◽

Receptor Blockers ◽

Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Download Full-text